Coencapsulation of Arsenic‐ and Platinum‐based Drugs for Targeted Cancer Treatment

Abstract

Two in one: A novel strategy for efficiently coencapsulating both arsenic- and platinum-based drugs into 100 nm-scale liposomes (NBs) relies on the formation of PtII–AsIII adducts. This co-loaded system presents a robust platform for further modification with targeting ligands and affords a method of improving the therapeutic efficacy of anticancer agents. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.